Codex DNA, Inc. announced revenue guidance for the full year 2022. For the year, the company expected Total Revenue in the range of $19 million to $21 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.7 USD | -0.27% |
|
-2.37% | -48.48% |
09/05 | Earnings Flash (TBIO) TELESIS BIO Reports Q1 Revenue $3.4M | MT |
09/05 | Telesis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.48% | 62.26L | |
+4.85% | 21TCr | |
+9.86% | 19TCr | |
+31.11% | 16TCr | |
+34.08% | 11TCr | |
+1.90% | 6.4TCr | |
+19.45% | 5.49TCr | |
+1.63% | 4.88TCr | |
-3.12% | 3.93TCr | |
+1.93% | 3.6TCr |
- Stock Market
- Equities
- TBIO Stock
- News Telesis Bio, Inc.
- Codex DNA, Inc. Announces Revenue Guidance for the Full Year 2022